Amgen CEO says U.S. Medicare out-of-pocket cap will improve access

1 min read
FILE PHOTO: Amgen Chairman and CEO Robert Bradway speaks during an interview on the sidelines of the 38th Annual JP Morgan Healthcare Conference in San Francisco

By Deena Beasley

– A proposed cap on out-of-pocket drug costs for Medicare recipients would improve patient access, but allowing the U.S. government health plan for seniors to negotiate prices could limit innovation, Amgen Inc Chief Executive Robert Bradway said in an interview.

“We need to make sure to be very careful not to destroy the very system which is bringing forward the innovation we need,” Bradway said in an interview ahead of the Reuters Total Health conference, which will run virtually from Nov. 15-18.

The latest legislation proposed by congressional Democrats and the Biden administration would give the federal government the ability for the first time to negotiate prices for a limited number of drugs paid for by Medicare.

Conventional prescription drugs would be protected from negotiation for the first nine years after they are launched, while biologic drugs, which are made from living cells, would be protected for 12 years.

The agreement would also set a $2,000 annual cap on out-of-pocket costs for Medicare recipients and limit annual price increases to the rate of inflation.

“We’re going to look favorably on anything that improves access,” Bradway said.

But he warned that allowing the government to “negotiate or in effect set prices,” runs the risk of “artificial distortions in the market with the effect that innovators will have to decide whether to reallocate capital away from the drug sector.”

Breaking News:  S&P 500 ends down as Apple dips and traders eye Powell speech

Bradway said more also needs to be known about the Biden administration’s efforts to agree with other nations on a multinational corporate tax rate.

A group of 136 countries, including the United States, last month set a goal for a minimum global tax rate of 15% for big companies – well below the current average of 23.5% in industrialized countries.

“It will be important if the U.S. wants to continue to be the epicenter of innovation for the U.S. to remain competitive,” Bradway said. “Otherwise, we’ll see what has been happening for years, which is investors from outside the United States acquiring innovative technology and basing that technology in lower tax jurisdictions.”

Amgen, based in Thousand Oaks, California, is one of the world’s largest makers of biotechnology drugs, including treatments for cancer, osteoporosis and rheumatoid arthritis.

(Reporting by Deena Beasley in Los Angeles; Editing by Matthew Lewis)